The temporal changes of disordered mineral metabolism in CKD patients are well‐established, with a progressive rise in circulating fibroblast growth factor (FGF) 23 (FGF23) early in the course of CKD, followed by secondary hyperparathyroidism and hyperphosphataemia in the late stages [12]. This evidence concerns the gene FGF23 and hyperphosphatemia.